

LBA22

Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase III ASCENT-04/KEYNOTE-D19 study

E. de Azambuja¹, P. Schmid², K.M. Kalinsky³, S. Loi⁴, S-B. Kim⁵, C. Yam⁶, B.L. Rapoport⁷, S-A. Im⁸, B. Pistilli⁹, W. Mchayleh¹⁰, D.W. Cescon¹¹, J. Watanabe¹², M.A. Lara Bañuelas¹³, R. Freitas¹⁴, F.J. Salvador Bofill¹⁵, X. Wang¹⁶, Y. Zhang¹⁷, L. Shi¹⁸, A. Chen¹⁹, S.M. Tolane²⁰

¹ Academic Trials Promoting Team, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Brussels, Belgium, ² Centre of Experimental Cancer Medicine, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, United Kingdom, ³ Medicine Dept., Winship Cancer Institute of Emory University, Atlanta, United States of America, ⁴ Translational Breast Cancer Genomics Lab - Research, Peter MacCallum Cancer Centre, Melbourne, Australia, ⁵ Department of Oncology, Asan Medical Center - University of Ulsan, Seoul, Republic of Korea, ⁶ Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America, ⁷ Department of Medical Oncology, The Medical Oncology Centre of Rosebank, Johannesburg, South Africa, ⁸ Internal Medicine Dept, SNUH - Seoul National University Hospital, Seoul, Republic of Korea, ⁹ Breast Cancer Dept., Institut Gustave Roussy, Villejuif, France, ¹⁰ Hematology and Medical Oncology, AdventHealth Cancer Institute, Altamonte Springs, United States of America, ¹¹ Medical Oncology Department, Princess Margaret Cancer Centre, Toronto, Canada, ¹² Department of Breast Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan, ¹³ Oncology Department, Oncology Center of Chihuahua, Chihuahua, Mexico, ¹⁴ Advanced Center for Diagnosis of Breast Diseases, CORA – Advanced Center for Diagnosis of Breast Diseases, Federal University of Goiás, State of Goiás, Brazil, ¹⁵ Medical Oncology Department, Hospital Universitario Virgen de Valme, Seville, Spain, ¹⁶ HEOR, Gilead Sciences, Inc., San Francisco, United States of America, ¹⁷ Biostatistics, Gilead Sciences, Inc., Foster City, United States of America, ¹⁸ Department of Evidence Synthesis, Modeling & Communication, Evidera - Waltham, Waltham, United States of America, ¹⁹ Development Department, Gilead Sciences, Inc., Foster City, United States of America²⁰ Department of Medical Oncology, Dana Farber Cancer Institute, Boston, United States of America

Background

In the ASCENT-04/KEYNOTE-D19 study (NCT05382286), first-line SG + pembro led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs chemo + pembro in pts with PD-L1+ (combined positive score ≥ 10) mTNBC. We report PROs from this study.

Methods

Pts were randomized to SG + pembro or chemo (gemcitabine + carboplatin, paclitaxel, nab-paclitaxel) + pembro. Time to first meaningful deterioration or death (TTD, defined as meaningful within-patient change [MWPC] from baseline ≥ 13.33 points for physical functioning and ≥ 10 -point for other domains) and least squares mean (LSM) change from baseline in EORTC QLQ-C30 domains in the intent-to-treat population were reported. A sensitivity analysis (with 20-point MWPC threshold) was undertaken for TTD in physical functioning. Data were analyzed by a Cox model.

Results

Analyses included 443 pts (221, SG + pembro; 222, chemo + pembro). TTD was comparable across most domains, including physical functioning, but favored SG + pembro for emotional functioning and pain (Table). However, SG + pembro had longer TTD in physical functioning in the sensitivity analysis (HR 0.82 [95% CI 0.60, 1.11]). Mean change from baseline favored SG + pembro for physical, role, and emotional functioning, pain, and insomnia. Worsening of nausea/vomiting and diarrhea were observed with SG + pembro (Table).Table: LBA22

Domain	TTD ^a HR (95% CI)	LSM change from BL ^b	Difference (95% CI)
Global health status/QOL	0.98 (0.75, 1.27)	1.10 (-1.40, 3.59)	
Physical functioning	0.95 (0.73, 1.22)	2.45 (0.09, 4.81)	
Role functioning	1.01 (0.79, 1.29)	3.34 (0.13, 6.55)	
Emotional functioning	0.71 (0.53, 0.96)	4.07 (1.20, 6.93)	
Cognitive functioning	0.96 (0.74, 1.23)	1.00 (-1.63, 3.63)	
Fatigue	0.91 (0.72, 1.15)	-2.75 (-5.65, 0.15)	

Domain	TTD ^a HR (95% CI)	LSM change from BL ^b Difference (95% CI)
Nausea/vomiting	1.38 (1.07, 1.77)	2.67 (0.73, 4.62)
Pain	0.75 (0.57, 0.98)	-5.39 (-8.55, -2.23)
Insomnia	0.75 (0.56, 1.00)	-4.59 (-7.70, -1.48)
Diarrhea	1.92 (1.48, 2.48)	10.41 (7.53, 13.29)

^aHR < 1 favors SG + pembro.^bDifference > 0 for functioning domains and < 0 for symptom domains favors SG + pembro.

Conclusions

SG + pembro maintained overall quality of life with reduced symptom burden and improved functioning in multiple domains. Worsening of nausea/vomiting and diarrhea are consistent with the known safety profile of SG. These data, along with the improvement in PFS, support SG + pembro as a potential new standard of care in pts with previously untreated PD-L1+ mTNBC.

Clinical trial identification

NCT05382286.

Editorial acknowledgement

Medical writing and editorial support was provided by Sonal S. Joshi, PhD, of Parexel, and funded by Gilead Sciences, Inc.

Legal entity responsible for the study

Gilead Sciences, Inc.,.

Funding

This study is sponsored by Gilead Sciences, Inc., and is in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Disclosure

E. de Azambuja: Financial Interests, Personal, Advisory Board: Roche/GNE, Novartis, SeaGen, MSD; Financial Interests, Personal, Invited Speaker: Zodiac, Libbs, Pierre Fabre, Lilly, AstraZeneca, Gilead Sciences; Financial Interests, Personal, Other, Chair of the Gilead Sciences Research Scholars Program in Solid Tumours: Gilead Sciences; Financial Interests, Personal, Other, Roche WO43571 IDMC: Roche/Genentech; Financial Interests, Institutional, Research Grant: Roche/GNE, AstraZeneca, GSK/Novartis, Servier; Financial Interests, Institutional, Other, Travel Grant: Roche/GNE; Financial Interests, Institutional, Local PI: MSD, ABCSG, Nektar, Gilead, Immunomedics, Synthon, Odonate Therapeutics; Financial Interests, Steering Committee Member, ASCENT 04: Gilead; Financial Interests, Steering Committee Member, Aphinity, Lorelei, Impassion03: Roche; Financial Interests, Steering Committee Member, AURORA: Breast International Group; Financial Interests, Steering Committee Member, Olympia: AstraZeneca; Financial Interests, Personal, Other, Travel grant: AstraZeneca; Financial Interests, Personal, Other, Travel Grant SABCS 2024: Gilead; Financial Interests, Institutional, Other, Scholarship grant for 2025-2026 for Luca Arecco: Gilead Sciences; Financial Interests, Institutional, Coordinating PI, Research grant for the TUCANIBE retrospective study: Pfizer; Non-Financial Interests, Advisory Role, Member of the cardio-oncology council: European Society of Cardiology (ESC), Belgian Society of Cardiology; Non-Financial Interests, Advisory Role, Belgium governmental institution for cancer: KCE; Non-Financial Interests, Other, Editorial board member: ESMO Open; Non-Financial Interests, Advisory Role: Anticancer Fund; Non-Financial Interests, Leadership Role, President 2023-2026: Belgian Society of Medical Oncology (BSMO). P. Schmid: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Pfizer, Roche, Gilead, Daiichi Sankyo, MSD, Bicycle Therapeutics, Lilly, Summit Therapeutics, Olema Oncology; Financial Interests, Personal, Invited Speaker: Menarini-Stemline, Gilead, AstraZeneca, Daiichi Sankyo, MSD, Roche; Financial Interests, Institutional, Research Grant: AstraZeneca, Genentech, Roche. K.M. Kalinsky: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Eli Lilly, Pfizer, Novartis, AstraZeneca, Merck, Seattle Genetics, Puma, Genentech, Gilead, Menarini, myovant, Takeda, Mersana Therapeutics, proteinquire, biotheranostics, Regor, Relay Therapeutics; Financial Interests, Personal, Stocks/Shares, Employment + Stock = spouse: Grail; Financial Interests, Personal, Stocks/Shares, Spouse: ADC Therapeutics; Financial Interests, Personal and Institutional, Local PI, Consultant: Novartis, Eli Lilly, AstraZeneca, daicchi sankyo; Financial Interests, Personal and Institutional, Local PI, consultant: Genentech; Financial Interests, Institutional, Local PI, consultant: Pfizer; Financial Interests, Institutional, Local PI: Seattle Genetics, Ascentantage; Financial Interests, Personal, Other, Consultant: Myovant, Takeda, Menarini, Prelude; Financial Interests, Personal, Other, consultant: RayzeBio; Other, Other, Support for attending meetings and/or travel: Eli Lilly, AstraZeneca, Pfizer; Other, Other, Steering Committee: Immunomedics, AstraZeneca, Ambryx, Genentech. S. Loi: Financial Interests, Institutional, Advisory Board, Consultant: AstraZeneca / Daiichi Sankyo, Novartis, Roche Genentech; Financial Interests, Institutional, Advisory Board, COnsultant: BMS; Financial Interests, Institutional, Advisory Board, consultant: Eli Lilly, Gilead Sciences, MSD; Financial Interests, Personal, Advisory Board: Novartis, AstraZeneca / Daiichi Sankyo, BMS, Amaroq Therapeutics, Mersana Therapeutics, Domain Therapeutics, Menari Asia-Pacific, Gilead

Sciences, MSD, Roche Genentech, Bicycle Therapeutics; Financial Interests, Institutional, Funding: Novartis, BMS, MSD, Eli Lilly, Nektar Therapeutics, AstraZeneca / Daiichi Sankyo, Roche - Genentech, Gilead Sciences, Pfizer; Non-Financial Interests, Advisory Role, Consultant (Non remunerated): Seattle Genetics, Novartis, Bristol Myers Squibb, Merck, AstraZeneca, Roche Genentech; Non-Financial Interests, Advisory Role, consultant (not compensated): Eli Lilly, Gilead Therapeutics. S. Kim: Financial Interests, Personal, Advisory Board: Novartis, AstraZeneca, Lilly, DaeHwa Pharma, Daiich-Sankyo, BeiGene, BNT; Financial Interests, Personal, Other, Medical travel: Lilly; Financial Interests, Personal, Ownership Interest: GenoPeaks; Financial Interests, Institutional, Research Grant: Novartis, Sanofi-Genzyme, DongKook Pharm Co. C. Yam: Financial Interests, Institutional, Advisory Board, reimbursement for travel: Gilead; Financial Interests, Institutional, Invited Speaker: MDHealth Brazil, Binaytara Foundation; Financial Interests, Institutional, Local PI: Gilead, Amgen, Merck, Pfizer, Astellas, Genentech, Novartis, BostonGene; Financial Interests, Institutional, Research Grant: GSK; Financial Interests, Institutional, Steering Committee Member: Gilead; Non-Financial Interests, Advisory Role, Scientific Advisory Board: CytoDyn. B.L. Rapoport: Financial Interests, Personal, Advisory Board: Merck & Co., Inc, Roche South Africa, Sandoz, Novartis South Africa, J&J South Africa, Pfizer South Africa, AstraZeneca South Africa. S. Im: Financial Interests, Personal, Advisory Board, no payment: AstraZeneca, Novartis, Eisai, Roche, Pfizer, Lilly, MSD, GSK, Daiichi Sankyo; Financial Interests, Institutional, Research Grant: AstraZeneca, Pfizer, Roche, Eisai; Financial Interests, Institutional, Local PI, Clinical Trial Budget: AstraZeneca, Novartis, Roche, Pfizer, Daiichi Sankyo, MSD, Lilly; Financial Interests, Institutional, Coordinating PI, Clinical Trial Budget: Eisai; Financial Interests, Institutional, Research Grant, Clinical Trial Budget: Boryung Pharm. B. Pistilli: Financial Interests, Institutional, Advisory Board: AstraZeneca, Seagen, Lilly, Daiichi Sankyo, MSD; Financial Interests, Institutional, Invited Speaker: Gilead, Novartis; Financial Interests, Personal, Advisory Board: Pierre Fabre, Daiichi Sankyo; Financial Interests, Personal, Other, travel support: AstraZeneca, Pierre Fabre, MSD, Daiichi Sankyo; Financial Interests, Personal, Other, Travel support: Pfizer; Financial Interests, Institutional, Advisory Board, Advisory Board and member of Steering Committee: Olema; Financial Interests, Institutional, Steering Committee Member: AstraZeneca, Novartis; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Local PI: AstraZeneca, Gilead, Seagen, MSD, Novartis; Financial Interests, Institutional, Funding: Daiichi Sankyo; Non-Financial Interests, Project Lead: UNICANCER. W. Mchayleh: Financial Interests, Personal, Invited Speaker: AstraZeneca, Daiichi Sankyo, Daiichi Sankyo, Gilead, Lilly, Menarini-Stemline, Merck, Natera; Financial Interests, Personal, Advisory Board: AstraZeneca, Gilead, Lilly, Menarini-Stemline; Financial Interests, Personal, Stocks/Shares: BMS, Relay Therapeutics, tempus, Natera. D.W. Cescon: Financial Interests, Personal, Advisory Board: AstraZeneca, Daiichi Sankyo, Exact Science, GenomeRx, Gilead, Lilly, Merck, Novartis, Pfizer, Roche, SAGA; Financial Interests, Institutional, Funding, Research funding (non-clinical), Local PI, Steering Committee Member: AstraZeneca; Financial Interests, Institutional, Research Grant: GenomeRx, ProteinQure; Financial Interests, Institutional, Local PI: Gilead, Pfizer; Financial Interests, Institutional, Funding, Research Funding, Local PI and Steering Committee Member: GSK; Financial Interests, Institutional, Funding, Research: Grail; Financial Interests, Institutional, Other, Collaborative Research Agreement: Guardant Health; Financial Interests, Institutional, Other, Research funding and in-kind support: Inivata/NeoGenomics; Financial Interests, Institutional, Other, In kind support of research: Knight Therapeutics; Financial Interests, Institutional, Funding, Local PI and Steering Committee Member: Merck; Non-Financial Interests, Advisory Role: Canadian Breast Cancer Network. J. Watanabe: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly Japan, Gilead Sciences, MSD, Pfizer; Financial Interests, Institutional, Local PI: AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly Japan, Gilead Sciences, MSD, Pfizer; Non-Financial Interests, Leadership Role: Japanese Breast Cancer Society, Japan Organization of Hereditary Breast and Ovarian Cancer; Non-Financial Interests, Member: American Society of Clinical Oncology, European Society For Medical Oncology. M.A. Lara Bañuelas: Financial Interests, Personal, Advisory Board: MSD; Non-Financial Interests, Principal Investigator: Gilead. R. Freitas Jr: Financial Interests, Institutional, Invited Speaker: Novartis, MSD, Gilead, AstraZeneca, Zeiss, Roche, Daichii Sankyo; Financial Interests, Institutional, Advisory Board: Daichii Sankyo. F.J. Salvador Bofill: Financial Interests, Personal, Invited Speaker: Daichy, Novartis, Lilly, Pfizer; Financial Interests, Institutional, Trial Chair: Lilly; Non-Financial Interests, Principal Investigator: Daichy, Novartis, Lilly, Gilead, Lilly. X. Wang: Financial Interests, Institutional, Stocks/Shares: Gilead Sciences; Financial Interests, Institutional, Full or part-time Employment: Gilead Sciences. Y. Zhang: Financial Interests, Personal, Full or part-time Employment, I am a full time employee at Gilead Sciences, Inc. since 01Aug2022.: Gilead Sciences, Inc.; Financial Interests, Personal, Full or part-time Employment, I was a full time employee at Amgen from 28Oct2019 to 29Jul2022.: Amgen; Financial Interests, Personal, Stocks/Shares, I own stock of Gilead Sciences: Gilead Sciences, Inc. L. Shi: Financial Interests, Institutional, Full or part-time Employment, Receiving salary from this company: Evidera, Inc; Financial Interests, Institutional, Stocks/Shares, Receiving stocks as an employee: Thermofisher; Financial Interests, Institutional, Funding, Evidera was paid by Gilead to provide consultation and support services.: Gilead; Financial Interests, Institutional, Funding, Evidera was paid by BMS to provide consultation and support services.: BMS; Financial Interests, Institutional, Funding, Evidera was paid by AstraZeneca to provide consultation and support services.: AstraZeneca; Financial Interests, Institutional, Funding, Evidera was paid by Takeda to provide consultation and support services.: Takeda Pharmaceuticals; Financial Interests, Institutional, Funding, Evidera was paid by DSI to provide consultation and support services.: Daiichi Sankyo. A. Chen: Financial Interests, Personal, Full or part-time Employment: Gilead Sciences; Financial Interests, Personal, Stocks/Shares: Gilead Sciences. S.M. Tolaney: Financial Interests, Personal, Other, Consulting: Aadi BioPharma; Financial Interests, Personal, Advisory Board, Ad board participation: Artios, BeyondSprings, Bicycle Therapeutics; Financial Interests, Personal, Advisory Board, Ad Board Participant/Consultant: AstraZeneca, Eli Lilly; Financial Interests, Personal, Advisory Board, Advisory Board participation: Bayer, Sumitovant Biopharmaceuticals, Natera; Financial Interests, Personal, Other, Consultant: Blueprint Medicines; Financial Interests, Personal, Advisory Board, Ad board participant: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board, Ad board participant/consultant: Daichii Sankyo, Eisai, Genentech/Roche, Gilead, Novartis, Sanofi, SeaGen; Financial Interests, Personal, Advisory Board, Advisory Board participation/consulting: Menarini/Stemline, BeOne Medicines; Financial Interests, Personal, Advisory Board, Ad Board participant/consultant: Merck; Financial Interests, Personal, Advisory Board, Ad board participant/Consultant: Pfizer; Financial Interests, Personal, Advisory Board, Advisory board participation: Reveal Genomics, Launch Therapeutics; Financial Interests, Personal, Advisory Board, Advisory board/consulting: Jazz Pharma; Financial Interests, Personal,

Advisory Board: Tango Therapeutics, Systimmune, eFFECTOR, Cullinan Oncology, Arvinas; Financial Interests, Personal, Advisory Board, Ad Board participation: Summit Therapeutics; Financial Interests, Personal, Advisory Board, ad board participation: BioNTech, Circle Pharma; Financial Interests, Personal, Advisory Board, Ad board/consulting participation: Zuellig Pharma; Financial Interests, Personal, Advisory Board, ad board/consulting participation: Johnson&Johnson/Ambrx; Financial Interests, Personal, Advisory Board, Advisory Board participation and consulting activities: Mersana Therapeutics; Financial Interests, Institutional, Coordinating PI, And steering committing: AstraZeneca; Financial Interests, Institutional, Local PI, And steering committee: Eli Lilly, Jazz Pharmaceuticals; Financial Interests, Institutional, Local PI: Pfizer, SeaGen, Novartis, Nanostring; Financial Interests, Institutional, Funding: Exelixis, OncoPep; Financial Interests, Institutional, Coordinating PI, and steering committee: Gilead; Financial Interests, Institutional, Local PI, and steering committee: Merck, Genentech/Roche, Stemline/Menarini.

© *European Society for Medical Oncology*